| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,349 |
3,454 |
$243K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,658 |
4,363 |
$161K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
927 |
820 |
$35K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,758 |
758 |
$17K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
646 |
577 |
$6K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
49 |
38 |
$2K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
29 |
24 |
$2K |
| 87807 |
|
131 |
116 |
$1K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
33 |
29 |
$1K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
27 |
12 |
$549.09 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
37 |
33 |
$133.20 |
| 90688 |
|
15 |
14 |
$129.20 |
| 81002 |
|
49 |
40 |
$120.96 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
12 |
12 |
$0.00 |